• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Cel-Sci Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    12/31/24 4:15:35 PM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CVM alert in real time by email
    cvm_8k.htm
    0000725363false00007253632024-12-292024-12-29iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of Report (date of earliest event reported): December 29, 2024

     

    CEL-SCI CORPORATION

    (Exact name of Registrant as specified in its charter)

     

    Colorado

     

    001-11889

     

    84-0916344

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File No.)

     

    (IRS Employer

    Identification No.)

     

    8229 Boone Blvd. #802

    Vienna, VA 22182

     

    (Address of principal executive offices, including Zip Code)

     

    Registrant’s telephone number, including area code: (703) 506-9460

     

    N/A

    (Former name or former address if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of Each Class

     

    Trading Symbol(s)

     

    Name of Each Exchange on Which Registered

    Common Stock, par value $0.01 per share

     

    CVM

     

    NYSE American

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§203.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§204.12b-2 of this chapter.

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

    Item 1.01 Entry into a Material Definitive Agreement.

     

    On December 29, 2024, CEL-SCI Corporation, a Colorado corporation (the “Company”), entered into a Placement Agency Agreement with ThinkEquity LLC (the “Placement Agent”) relating to the sale and issuance of 7,552,500 shares of the Company’s common stock, at an offering price of $0.31 per share (the “Shares”), and pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 8,577,500 shares of common stock, at an offering price of $0.3099 per Pre-Funded Warrant (such sale and issuance, the “Offering”). The Pre-Funded Warrants are immediately exercisable and shall expire when exercised in full, at an exercise price of $0.0001 per share.

     

    The Offering closed on December 31, 2024.  The gross proceeds from the Offering were approximately $5,000,000 before deducting Placement Agent fees and other offering expenses payable by the Company, and exclusive of the Pre-Funded Warrant exercise price. The Company intends to use the net proceeds from the Offering to fund the continued development of Multikine, for general corporate purposes, and working capital.

     

    The securities were offered and sold by the Company pursuant to the Company’s effective registration statement on Form S-3 (Registration No. 333-265995) which was declared effective by the Securities Exchange and Commission (the “SEC”) on July 15, 2022, the base prospectus included therein, as amended and supplemented by the prospectus supplement dated December 29, 2024.

     

    Pursuant to the terms of the Placement Agency Agreement, the Company agreed to pay the Placement Agent a cash fee equal to 7.0% of the gross proceeds of the Offering and to reimburse the Placement Agent for certain of its expenses in an aggregate amount up to $110,000. The Company further agreed not to issue, enter into any agreement to issue or announce the issuance or proposed issuance of, any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock or file any registration statement or prospectus, or any amendment or supplement thereto for a period of 30 days from December 29, 2024, subject to certain exceptions. Additionally, each of the directors and officers of the Company, pursuant to lock-up agreements, agreed not to sell or transfer any of the Company securities which they hold, subject to certain exceptions, for a period of 45 days from December 29, 2024.

     

    The Placement Agency Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Placement Agent, including for liabilities under the Securities Act of 1933, as amended (the “Securities Act”), other obligations of the parties and termination provisions. The foregoing description of the Placement Agency Agreement is not complete and is qualified in its entirety by reference to the full text of the Placement Agency Agreement, a copy of which is filed herewith as Exhibit 1.1 to this Current Report on Form 8-K and is incorporated herein by reference.

     

    This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the securities discussed herein, nor shall there be any offer, solicitation, or sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

     

     
    2

     

     

    Item 8.01 Other Events.

     

    On December 29, 2024, the Company issued a press release announcing the pricing of the Offering, which press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

     

    On December 31, 2024, the Company issued a press release announcing the closing of the Offering. A copy of this press release is attached as Exhibit 99.2.

     

    The information in this Item 8.01, including Exhibit 99.1 and 99.2 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference in any filing under the Securities Act  or the Exchange Act, except as expressly set forth by specific reference in such a filing.

     

    Forward-Looking Statements

     

    Certain of the statements made in this Current Report on Form 8-K are forward looking. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. More information about the risks and uncertainties faced by the Company is contained under the caption “Risk Factors” in the Company’s prospectus supplement filed with the SEC on December 30, 2024 pursuant to Rule 424(b)(5) promulgated under the Securities Act, the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2023 filed with the SEC on December 21, 2023, and other filings made by the Company with the SEC, all of which can be obtained on the SEC’s website at www.sec.gov. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. The Company expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

     

    Item 9.01 Financial Statements and Exhibits.

     

    Exhibit No.

     

    Description

    1.1

     

    Placement Agency Agreement dated December 29. 2024, by and between CEL-SCI Corporation and ThinkEquity, LLC

    4.1

     

    Form of Pre-Funded Warrant

    5.1

     

    Opinion of Hart & Hart, LLC

    23.1

     

    Consent of Hart & Hart, LLC (included in Exhibit 5.1)

    99.1

     

    Press Release dated December 29, 2024

    99.2

     

    Press Release dated December 31, 2024

     

     
    3

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: December 31, 2024

     

     

    CEL-SCI CORPORATION

     

     

     

     

     

     

    By:

    /s/ Geert Kersten

     

     

     

    Geert Kersten

     

     

     

    Chief Executive Officer

     

     

     
    4

     

    Get the next $CVM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CVM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CVM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Scientific Officer Talor Eyal was granted 10,416 shares, increasing direct ownership by 8% to 135,013 units (SEC Form 4)

      4 - CEL SCI CORP (0000725363) (Issuer)

      4/1/25 9:51:43 AM ET
      $CVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Prichep Patricia B was granted 15,432 shares, increasing direct ownership by 6% to 266,230 units (SEC Form 4)

      4 - CEL SCI CORP (0000725363) (Issuer)

      4/1/25 9:49:33 AM ET
      $CVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Executive Officer Kersten Geert R was granted 22,786 shares, increasing direct ownership by 2% to 1,240,378 units (SEC Form 4)

      4 - CEL SCI CORP (0000725363) (Issuer)

      4/1/25 9:46:47 AM ET
      $CVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CVM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia—Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market

      Concluded a successful meeting with Saudi Food and Drug Authority CEL-SCI was encouraged to apply for Conditional Approval with Breakthrough Therapy Designation based on data from its concluded Phase 3 study Evaluating Saudi Arabia-based partnerships to potentially fund local manufacturing and launch Multikine throughout the region CEL-SCI Corporation (NYSE:CVM) today announced that it met with the Saudi Food and Drug Authority (SFDA) to discuss the development of Multikine cancer immunotherapy* (Leukocyte Interleukin, Injection), the vast amount of Multikine data available to support a marketing application for its use as a treatment of head and neck cancer, and the possible pathway

      4/23/25 8:30:00 AM ET
      $CVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • New Study in the Scientific Journal "Cancer Cell" Supports CEL-SCI's Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses

      Head and neck cancer patients treated with Multikine who had complete or partial tumor responses before surgery had improvements in overall survival, suggesting pre-surgical tumor response is a strong indicator of efficacy and leads to improved overall survival A third-party head and neck cancer study published in "Cancer Cell" confirms the observation that pre-surgical tumor responses in head and neck cancer leads to improved survival CEL-SCI Corporation (NYSE:CVM) today announced that a study titled "Distinct CD8+ T cell dynamics associate with response to neoadjuvant cancer immunotherapies" by Li Housaiyin et. al., Cancer Cell (2025) provides support for CEL-SCI's approach aimed at see

      4/8/25 9:51:00 AM ET
      $CVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients

      Data published in peer-reviewed scientific journal Pathology and Oncology Research Quality of life improvements included reduction in or cessation of pain in the head and neck area, improvement or complete restoration in ability to eat, drink, and swallow, ability for selfcare including walking and using the toilet, and improved emotional wellbeing Complete responders to Multikine treatment reported a 100% (wherein all respondents scored the highest possible improvement from baseline) on 60% (39/65) quality of life measures 89.4% of partial responders to Multikine reported improved quality of life measures Multikine is headed into a final confirmatory Registration Study in head and neck

      3/24/25 9:00:00 AM ET
      $CVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CVM
    Leadership Updates

    Live Leadership Updates

    See more

    $CVM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results

      CEL-SCI Corporation (NYSE:CVM) today reported financial results for the quarter ended June 30, 2024, as well as key recent clinical and corporate developments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240815767286/en/The table includes detailed results from the bias analysis. (Graphic: Business Wire) Clinical and Corporate Developments include: In July 2024, following the end of the third fiscal quarter, CEL-SCI reported the results of a bias analysis. The bias analysis, a standard process to ensure a trial's findings are reliable, was conducted in preparation for CEL-SCI's upcoming confirmatory Registration Study. This

      8/15/24 8:00:00 AM ET
      $CVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CEL-SCI Appoints Robert Watson as Chairperson of the Board

      CEL-SCI Corporation (NYSE:CVM) today announced that Robert ("Bob") Watson, who has served as a Director of the Company since 2017, has been appointed Chairperson of the Board. Bob is an accomplished business leader who began his career as an investment banker. With over four decades of experience across various healthcare markets, Bob brings extensive expertise in capital formation strategies and partnerships to drive an efficient capital structure. During his career as CEO or President of private and publicly traded companies in the healthcare sector, Bob negotiated over a half dozen exits and more than $750 million in capital transactions including IPOs, secondary offerings, and debt in

      7/8/24 9:15:00 AM ET
      $CVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CEL-SCI Appoints Mario Gobbo to Its Board of Directors

      CEL-SCI Corporation (NYSE:CVM) today announced the appointment of Mario Gobbo to its Board of Directors. Mr. Gobbo has nearly 40 years of banking and corporate finance experience in healthcare and energy. His expertise encompasses venture capital and private equity as well as investment banking and strategic advisory services. He has served as an officer or director for a number of companies including several biotech companies: Xcovery, Ocimum/Genelogic and Helix BioPharma. Prior to that, Mr. Gobbo worked in the financial industry for Lazard LLC, Swiss Bank Corporation, the European Bank for Reconstruction and Development, Natixis Bleichroeder, Inc., and International Finance Corporation

      4/23/24 9:00:00 AM ET
      $CVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Watson Robert Eugene bought $27,800 worth of shares (20,000 units at $1.39), increasing direct ownership by 451% to 24,431 units (SEC Form 4)

      4 - CEL SCI CORP (0000725363) (Issuer)

      5/10/24 9:04:18 AM ET
      $CVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Prichep Patricia B bought $11,120 worth of shares (8,000 units at $1.39), increasing direct ownership by 4% to 232,326 units (SEC Form 4)

      4 - CEL SCI CORP (0000725363) (Issuer)

      5/9/24 1:07:10 PM ET
      $CVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kersten Geert R bought $41,700 worth of shares (30,000 units at $1.39), increasing direct ownership by 3% to 1,195,309 units (SEC Form 4)

      4 - CEL SCI CORP (0000725363) (Issuer)

      5/9/24 9:19:04 AM ET
      $CVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CVM
    SEC Filings

    See more
    • SEC Form DEF 14A filed by Cel-Sci Corporation

      DEF 14A - CEL SCI CORP (0000725363) (Filer)

      4/9/25 12:59:47 PM ET
      $CVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form PRE 14A filed by Cel-Sci Corporation

      PRE 14A - CEL SCI CORP (0000725363) (Filer)

      3/21/25 5:15:11 PM ET
      $CVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cel-Sci Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

      8-K - CEL SCI CORP (0000725363) (Filer)

      3/18/25 5:07:52 PM ET
      $CVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CVM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Cel-Sci Corporation (Amendment)

      SC 13G/A - CEL SCI CORP (0000725363) (Subject)

      2/8/23 10:48:28 AM ET
      $CVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Cel-Sci Corporation (Amendment)

      SC 13G/A - CEL SCI CORP (0000725363) (Subject)

      4/11/22 1:55:14 PM ET
      $CVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Cel-Sci Corporation (Amendment)

      SC 13G/A - CEL SCI CORP (0000725363) (Subject)

      2/11/22 7:53:04 AM ET
      $CVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care